Go to
JCI Insight
Citations to this article
Bezawit A. Woldemeskel, … , Caroline C. Garliss, Joel N. Blankson
Published April 6, 2021
Citation Information: J Clin Invest. 2021;131(10):e149335. https://doi.org/10.1172/JCI149335.
Citation Information: J Clin Invest. 2021;131(10):e149335. https://doi.org/10.1172/JCI149335.
Abstract
Recent studies have shown T cell cross-recognition of SARS-CoV-2 and common cold coronavirus spike proteins. However, the effect of SARS-CoV-2 vaccines on T cell responses to common cold coronaviruses (CCCs) remains unknown. In this study, we analyzed CD4+ T cell responses to spike peptides from SARS-CoV-2 and 3 CCCs (HCoV-229E, HCoV-NL63, and HCoV-OC43) before and after study participants received Pfizer-BioNTech (BNT162b2) or Moderna (mRNA-1273) mRNA-based COVID-19 vaccines. Vaccine recipients showed broad T cell responses to the SARS-CoV-2 spike protein, and we identified 23 distinct targeted peptides in 9 participants, including 1 peptide that was targeted in 6 individuals. Only 4 of these 23 targeted peptides would potentially be affected by mutations in the UK (B.1.1.7) and South African (B.1.351) variants, and CD4+ T cells from vaccine recipients recognized the 2 variant spike proteins as effectively as they recognized the spike protein from the ancestral virus. Interestingly, we observed a 3-fold increase in the CD4+ T cell responses to HCoV-NL63 spike peptides after vaccination. Our results suggest that T cell responses elicited or enhanced by SARS-CoV-2 mRNA vaccines may be able to control SARS-CoV-2 variants and lead to cross-protection against some endemic coronaviruses.
Authors
Bezawit A. Woldemeskel, Caroline C. Garliss, Joel N. Blankson
Citation information
Citations to this article (119)
| Title and authors | Publication | Year |
|---|---|---|
|
SARS-CoV-2 mRNA Vaccines Induce Cross-Reactive Antibodies to NL63 Coronavirus but Do Not Boost Pre-Existing Immunity Anti-NL63 Antibody Responses
Tang W, Chang ZW, Goh YS, Tan YJ, Hor PX, Loh CY, Lye DC, Young BE, Ng LF, Tay MZ, Rénia L |
Vaccines | 2025 |
|
A modular mRNA vaccine platform encoding antigen-presenting capsid virus-like particles enhances the immunogenicity of the malaria antigen Pfs25.
Fougeroux C, Hagen SH, Goksøyr L, Aves KL, Okholm AK, Morin C, Lokras AG, Baghel SS, Foged C, van de Vegte-Bolmer M, van Gemert GJ, Jore MM, Vidal-Calvo EE, Gustavsson T, Salanti A, Theander TG, Nielsen MA, de Jongh WA, Sander Bertelsen AF |
Nature nanotechnology | 2025 |
|
A quest for universal anti-SARS-CoV-2 T cell assay: systematic review, meta-analysis, and experimental validation.
Binayke A, Zaheer A, Vishwakarma S, Singh S, Sharma P, Chandwaskar R, Gosain M, Raghavan S, Murugesan DR, Kshetrapal P, Thiruvengadam R, Bhatnagar S, Pandey AK, Garg PK, Awasthi A |
npj Vaccines | 2024 |
|
People who use drugs show no increase in pre-existing T-cell cross-reactivity toward SARS-CoV-2 but develop a normal polyfunctional T-cell response after standard mRNA vaccination
Gainullin M, Federico L, Røkke Osen J, Chaban V, Kared H, Alirezaylavasani A, Lund-Johansen F, Wildendahl G, Jacobsen JA, Sarwar Anjum H, Stratford R, Tennøe S, Malone B, Clancy T, Vaage JT, Henriksen K, Wüsthoff L, Munthe LA |
Frontiers in immunology | 2024 |
|
DNA origami vaccine (DoriVac) nanoparticles improve both humoral and cellular immune responses to infectious diseases.
Zeng YC, Young OJ, Si L, Ku MW, Isinelli G, Rajwar A, Jiang A, Wintersinger CM, Graveline AR, Vernet A, Sanchez M, Ryu JH, Kwon IC, Goyal G, Ingber DE, Shih WM |
bioRxiv : the preprint server for biology | 2024 |
|
Sustained cell-mediated but not humoral responses in rituximab-treated rheumatic patients after vaccination against SARS-CoV-2.
Thomas Κ, Grigoropoulos I, Alexopoulou P, Karofylakis E, Galani I, Papadopoulou KK, Tsiavou A, Ntourou A, Mavrou E, Qevani I, Katsimbri P, Koutsianas C, Mavrea E, Vassilopoulos D, Pournaras S, Tsiodras S, Boumpas D, Antoniadou A |
Rheumatology (Oxford, England) | 2024 |
|
Immunogenicity and Tolerance of BNT162b2 mRNA Vaccine in Allogeneic Hematopoietic Stem Cell Transplant Patients.
Ben Khlil AA, Zamali I, Belloumi D, Gdoura M, Kharroubi G, Marzouki S, Dachraoui R, Ben Yaiche I, Bchiri S, Hamdi W, Gharbi M, Ben Hmid A, Samoud S, Galai Y, Torjmane L, Ladeb S, Bettaieb J, Triki H, Ben Abdeljelil N, Ben Othman T, Ben Ahmed M |
Human vaccines | 2024 |
|
A Cocktail of Lipid Nanoparticle-mRNA Vaccines Broaden Immune Responses against β-Coronaviruses in a Murine Model
Zhang Y, Zhang J, Li D, Mao Q, Li X, Liang Z, He Q |
Viruses | 2024 |
|
Current Understanding of the Immune Response after COVID-19 Vaccination
Ning S, Firinu D |
Human vaccines | 2024 |
|
The Influence of Cross-Reactive T Cells in COVID-19
Eggenhuizen PJ, Ooi JD |
Biomedicines | 2024 |
|
Bivalent mRNA COVID vaccines elicit predominantly cross-reactive CD4(+) T cell clonotypes.
Sop J, Traut CC, Dykema AG, Hunt JH, Beckey TP, Basseth CR, Antar AAR, Laeyendecker O, Smith KN, Blankson JN |
Cell reports. Medicine | 2024 |
|
Clonal structure and the specificity of vaccine-induced T cell response to SARS-CoV-2 Spike protein
Sheetikov SA, Khmelevskaya AA, Zornikova KV, Zvyagin IV, Shomuradova AS, Serdyuk YV, Shakirova NT, Peshkova IO, Titov A, Romaniuk DS, Shagina IA, Chudakov DM, Kiryukhin DO, Shcherbakova OV, Khamaganova EG, Dzutseva V, Afanasiev A, Bogolyubova AV, Efimov GA |
Frontiers in immunology | 2024 |
|
Effects of COVID-19 mRNA vaccination on HIV viremia and reservoir size.
Duncan MC, Omondi FH, Kinloch NN, Lapointe HR, Speckmaier S, Moran-Garcia N, Lawson T, DeMarco ML, Simons J, Holmes DT, Lowe CF, Bacani N, Sereda P, Barrios R, Harris M, Romney MG, Montaner JSG, Brumme CJ, Brockman MA, Brumme ZL |
AIDS | 2024 |
|
Post-COVID-19 Vaccination Meningitis and Meningoencephalitis: A Systematic Review of Case Series and Case Reports
Taiyeb Khosroshahi M, Hamidi S, Kangari P, Gharakhanlou S, Hamidi Z, Jafari-Sales A, Shamekh A, Bannazadeh Baghi H, Morsali S |
The American Journal of Tropical Medicine and Hygiene | 2024 |
|
Longitudinal Characterization of SARS-CoV-2 Immunity in Hemodialysis Patients Post Omicron
Karaba AH, Xue J, Johnston TS, Traut CC, Dalrymple LS, Kossmann RJ, Blankson JN, Parikh CR, Ray SC |
Kidney International Reports | 2024 |
|
Durability of Vaccine-Induced and Natural Immunity Against COVID-19: A Narrative Review
Pooley N, Abdool Karim SS, Combadière B, Ooi EE, Harris RC, El Guerche Seblain C, Kisomi M, Shaikh N |
Infectious Diseases and Therapy | 2023 |
|
Longitudinal monitoring of mRNA-vaccine-induced immunity against SARS-CoV-2
Monzon-Posadas WO, Zorn J, Peters K, Baum M, Proksch H, Schlüter CB, Menting T, Pušnik J, Streeck H |
Frontiers in immunology | 2023 |
|
Mouse models susceptible to HCoV-229E and HCoV-NL63 and cross protection from challenge with SARS-CoV-2
Liu D, Chen C, Chen D, Zhu A, Li F, Zhuang Z, Mok CK, Dai J, Li X, Jin Y, Chen Z, Sun J, Wang Y, Li Y, Zhang Y, Wen L, Zhang Z, Zhuo J, Wang J, Ran W, Wang D, Zhang S, Tang Y, Li S, Lai X, Wei P, Yuan J, Chen F, Huang S, Sun F, Qian Z, Tan W, Zhao J, Peiris M, Zhao J |
Proceedings of the National Academy of Sciences | 2023 |
|
Third and fourth vaccine doses broaden and prolong immunity to SARS-CoV-2 in immunocompromised adult patients
Michelle Cheung, Roya Dayam, Janna Shapiro, Jaclyn Law, Gary Chao, Daniel Pereira, Rogier Goetgebuer, David Croitoru, Joanne Stempak, Lily Acheampong, Saima Rizwan, Jenny D Lee, Liz Jacob, Darshini Ganatra, Ryan Law, Victoria E Rodriguez-Castellanos, Madeline Kern-Smith, Melanie Delgado-Brand, Genevieve Mailhot, Nigil Haroon, Robert Inman, Vincent Piguet, Vinod Chandran, Mark Silverberg, Tania Watts, Anne-Claude Gingras. |
Journal of immunology (Baltimore, Md. : 1950) | 2023 |
|
Persistence of Immune Response Elicited by Three Doses of mRNA Vaccine against SARS-CoV-2 in a Cohort of Patients with Solid Tumors: A One-Year Follow-Up
Lasagna A, Cassaniti I, Arena F, Bergami F, Percivalle E, Comolli G, Sarasini A, Ferrari A, Cicognini D, Schiavo R, Lo Cascio G, Pedrazzoli P, Baldanti F |
International journal of molecular sciences | 2023 |
|
mRNA melanoma vaccine revolution spurred by the COVID-19 pandemic
Xu Z, Fisher DE |
Frontiers in immunology | 2023 |
|
A Beta Strain-Based Spike Glycoprotein Vaccine Candidate Induces Broad Neutralization and Protection against SARS-CoV-2 Variants of Concern
Cao L, Guo J, Li H, Ren H, Xiao K, Zhang Y, Zhu S, Song Y, Zhao W, Wu D, Chen Z, Zhang Y, Xia B, Ji T, Yan D, Wang D, Yang Q, Zhou Y, Li X, Hou Z, Xu W |
Microbiology spectrum | 2023 |
|
Pre-existing humoral immunity and CD4(+) T cell response correlate with cross-reactivity against SARS-CoV-2 Omicron subvariants after heterologous prime-boost vaccination.
Shen CF, Fu YC, Ho TS, Chen PL, Lee NY, Tsai BY, Tsai PJ, Ko WC, Liu CC, Cheng CM, Shieh CC |
Clinical Immunology | 2023 |
|
Determinants of humoral and cellular immune responses to three doses of mRNA SARS-CoV-2 vaccines in older adults: a longitudinal cohort study
Ravussin A, Robertson AH, Wolf AS, Blix K, Kjønstad IF, Solum G, Feiring B, Strand BH, Lund-Johansen F, Munthe LA, Magnus P, Trogstad L, Mjaaland S |
2023 | |
|
Humoral and Cellular Response and Associated Variables Nine Months following BNT162b2 Vaccination in Healthcare Workers
Syrimi N, Sourri F, Giannakopoulou MC, Karamanis D, Pantousas A, Georgota P, Rokka E, Vladeni Z, Tsiantoula E, Soukara E, Lavda N, Gkaragkanis D, Zisaki A, Vakalidis P, Goula V, Loupou E, Palaiodimos L, Hatzigeorgiou D |
Journal of Clinical Medicine | 2023 |
|
SARS-CoV-2 bivalent mRNA vaccine with broad protection against variants of concern.
Ma Q, Li M, Ma L, Zhang C, Zhang H, Zhong H, Wen J, Wang Y, Yan Z, Xiong W, Wu L, Guo J, Yang W, Yang Z, Zhang B |
Frontiers in immunology | 2023 |
|
Immunogenicity and reactogenicity of inactivated SARS-CoV-2 vaccines in healthy adults
Wu Y, Huang P, Xu M, Zhao Q, Xu Y, Han S, Li H, Wang Y |
Frontiers in immunology | 2023 |
|
Immunopeptidome profiling of human coronavirus OC43-infected cells identifies CD4 T-cell epitopes specific to seasonal coronaviruses or cross-reactive with SARS-CoV-2.
Becerra-Artiles A, Nanaware PP, Muneeruddin K, Weaver GC, Shaffer SA, Calvo-Calle JM, Stern LJ |
PLoS pathogens | 2023 |
|
Bivalent COVID-19 Vaccines: Can the Original Antigenic Sin Be Forgiven?
Blankson JN |
The Journal of Infectious Diseases | 2023 |
|
A unique cytotoxic CD4+ T cell‐signature defines critical COVID‐19
Baird S, Ashley CL, Marsh\u2010Wakefield F, Alca S, Ashhurst TM, Ferguson AL, Lukeman H, Counoupas C, Post JJ, Konecny P, Bartlett A, Martinello M, Bull RA, Lloyd A, Grey A, Hutchings O, Palendira U, Britton WJ, Steain M, Triccas JA |
IBMS BoneKEy | 2023 |
|
A Paratope-Enhanced Method to Determine Breadth and Depth TCR Clonal Metrics of the Private Human T-Cell Vaccine Response after SARS-CoV-2 Vaccination
Li D, Pavlovitch-Bedzyk AJ, Ebinger JE, Khan A, Hamideh M, Merchant A, Figueiredo JC, Cheng S, Davis MM, McGovern DP, Melmed GY, Xu AM, Braun J |
International journal of molecular sciences | 2023 |
|
Immunogenicity and Efficacy of Vaccination in People Living with Human Immunodeficiency Virus
Tortellini E, Fosso Ngangue YC, Dominelli F, Guardiani M, Falvino C, Mengoni F, Carraro A, Marocco R, Pasculli P, Mastroianni CM, Ciardi MR, Lichtner M, Zingaropoli MA |
Viruses | 2023 |
|
CD4+ T-cells from COVID-19 mRNA vaccine recipients recognize a conserved epitope present in diverse coronaviruses.
Bezawit A. Woldemeskel, Arbor G Dykema, Caroline Garliss, Saphira Cherfils, Kellie N Smith, Joel Blankson |
Journal of Clinical Investigation | 2022 |
|
Adaptive immune responses in vaccinated patients with symptomatic SARS-CoV-2 Alpha infection
Han-Sol Park, Janna R. Shapiro, Ioannis Sitaras, Bezawit Woldemeskel, Caroline Garliss, Amanda Dziedzic, Jaiprasath Sachithanandham, Anne E Jedlicka, Christopher A. Caputo, Kimberly E Rousseau, Manjusha Thakar, San Suwanmanee, Pricila Hauk, Lateef Aliyu, Natalia I. Majewska, Sushmita Koley, Bela Patel, Patrick Broderick, Giselle Mosnaim, Sonya L. Heath, Emily S. Spivak, Aarthi Shenoy, Evan M. Bloch, Thomas J. Gniadek, Shmuel Shoham, Arturo Casadevall, Daniel Hanley, Andrea L Cox, Oliver Laeyendecker, Michael Betenbaugh, Steven M. Cramer, Heba H. Mostafa, Andrew Pekosz, Joel Blankson, Sabra L. Klein, Aaron Tobian, David Sullivan, Kelly A. Gebo |
JCI Insight | 2022 |
|
SARS-CoV-2 -specific immune responses in boosted vaccine recipients with breakthrough infections during the Omicron variant surge
Bezawit Woldemeskel, Caroline Garliss, Tihitina Y. Aytenfisu, Trevor S. Johnston, Evan J. Beck, Arbor G Dykema, Nicole Frumento, Desiree A. Wright, Andrew H Yang, Alexander I Damanakis, Oliver Laeyendecker, Andrea L Cox, Heba H. Mostafa, Andrew H Karaba, Joel Blankson |
JCI Insight | 2022 |
|
Immune response to SARS-CoV-2 vaccination in relation to peripheral immune cell profiles among patients with multiple sclerosis receiving ocrelizumab
S Räuber, M Korsen, N Huntemann, L Rolfes, T Müntefering, V Dobelmann, A Hermann, T Kölsche, K von Wnuck Lipinski, C Schroeter, C Nelke, L Regner-Nelke, J Ingwersen, M Pawlitzki, B Teegen, M Barnett, H Hartung, O Aktas, P Albrecht, B Levkau, N Melzer, T Ruck, S Meuth, D Kremer |
Journal of neurology, neurosurgery, and psychiatry | 2022 |
|
Sex, Age, and Ethnic Background Shape Adaptive Immune Responses Induced by the SARS-CoV-2 mRNA Vaccine
J Bai, A Chiba, G Murayama, T Kuga, N Tamura, S Miyake |
Frontiers in immunology | 2022 |
|
Progress and Challenges Toward Generation and Maintenance of Long-Lived Memory T Lymphocyte Responses During COVID-19
S Kumar, S Saxena, V Maurya, A Tripathi |
Frontiers in immunology | 2022 |
|
Comparison of Seroconversion in Children and Adults With Mild COVID-19
Z Toh, J Anderson, N Mazarakis, M Neeland, R Higgins, K Rautenbacher, K Dohle, J Nguyen, I Overmars, C Donato, S Sarkar, V Clifford, A Daley, S Nicholson, F Mordant, K Subbarao, D Burgner, N Curtis, J Bines, S McNab, A Steer, K Mulholland, S Tosif, N Crawford, D Pellicci, L Do, P Licciardi |
2022 | |
|
Minimal Crossover between Mutations Associated with Omicron Variant of SARS-CoV-2 and CD8 + T-Cell Epitopes Identified in COVID-19 Convalescent Individuals
A Redd, A Nardin, H Kared, E Bloch, B Abel, A Pekosz, O Laeyendecker, M Fehlings, T Quinn, A Tobian, S Goff |
mBio | 2022 |
|
SARS-CoV-2 vaccination diversifies the CD4+ spike-reactive T cell repertoire in patients with prior SARS-CoV-2 infection
A Dykema, B Zhang, B Woldemeskel, C Garliss, R Rashid, T Westlake, L Zhang, J Zhang, L Cheung, J Caushi, D Pardoll, A Cox, H Ji, K Smith, J Blankson |
EBioMedicine | 2022 |
|
The T cell immune response against SARS-CoV-2
P Moss |
Nature Immunology | 2022 |
|
SARS-CoV-2 infections in mRNA vaccinated individuals are biased for viruses encoding spike E484K and associated with reduced infectious virus loads that correlate with respiratory antiviral IgG levels
H Mostafa, C Luo, C Morris, M Li, N Swanson, A Amadi, N Gallagher, A Pekosz |
Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology | 2022 |
|
Third dose of anti-SARS-CoV-2 vaccine for patients with cancer: Should humoral responses be monitored? A position article
J Barrière, M Carles, C Audigier-Valette, D Re, Z Adjtoutah, B Seitz-Polski, V Gounant, D Descamps, G Zalcman |
European Journal of Cancer | 2022 |
|
Mitigating Covid-19 in the face of emerging virus variants, breakthrough infections and vaccine hesitancy
A Haque, A Pant |
Journal of Autoimmunity | 2022 |
|
Large-Scale Structure-Based Screening of Potential T Cell Cross-Reactivities Involving Peptide-Targets From BCG Vaccine and SARS-CoV-2
R Tarabini, M Rigo, A Fonseca, F Rubin, R Bellé, L Kavraki, T Ferreto, D Antunes, A de Souza |
Frontiers in immunology | 2022 |
|
Accuracy and real life performance of a novel interferon-γ release assay for the detection of SARS-CoV2 specific T cell response
D Huzly, M Panning, F Smely, M Enders, J Komp, V Falcone, D Steinmann |
Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology | 2022 |
|
Peculiarities of the T Cell Immune Response in COVID-19
D Kudlay, I Kofiadi, M Khaitov |
Human vaccines | 2022 |
|
Large inter-individual variability of cellular and humoral immunological responses to mRNA-1273 (Moderna) vaccination against SARS-CoV-2 in health care workers
A Krüttgen, G Haase, H Haefner, M Imöhl, M Kleines |
Clinical and Experimental Vaccine Research | 2022 |
|
Humoral and cellular responses after a third dose of SARS-CoV-2 BNT162b2 vaccine in patients with lymphoid malignancies
D Re, B Seitz-Polski, V Brglez, M Carles, D Graça, S Benzaken, S Liguori, K Zahreddine, M Delforge, B Bailly-Maitre, B Verrière, E Chamorey, J Barrière |
Nature Communications | 2022 |
|
Waning immune responses against SARS-CoV-2 variants of concern among vaccinees in Hong Kong
Q Peng, R Zhou, Y Wang, M Zhao, N Liu, S Li, H Huang, D Yang, K Au, H Wang, K Man, K Yuen, Z Chen |
EBioMedicine | 2022 |
|
Immunogenicity mechanism of mRNA vaccines and their limitations in promoting adaptive protection against SARS-CoV-2
M Salleh, M Norazmi, Z Deris |
PeerJ | 2022 |
|
Cellular Immunity—The Key to Long-Term Protection in Individuals Recovered from SARS-CoV-2 and after Vaccination
D Primorac, P Brlek, V Matišić, V Molnar, K Vrdoljak, R Zadro, M Parčina |
Human vaccines | 2022 |
|
A first-in-human trial of COVID-eVax, a cellular response-skewed DNA vaccine against COVID-19
Luigi Aurisicchio, Nadia Brambilla, Marina Cazzaniga, Paolo Bonfanti, Stefano Milleri, Paolo Ascierto, Serena Capici, Cristina Vitalini, Federica Girolami, Giampaolo Giacovelli, Gianfranco Caselli, Michela Visintin, Francesca Fanti, Matteo Ghirri, Antonella Conforti, Mirco Compagnone, Lucia Lione, Erika Salvatori, Alessia Muzi, Emanuele Marra, Fabio Palombo, Giuseppe Roscilli, Alessandro Manenti, Emanuele Montomoli, Matteo Cadossi, Lucio Rovati |
Molecular Therapy | 2022 |
|
TNF-α+ CD4+ T cells dominate the SARS-CoV-2 specific T cell response in COVID-19 outpatients and are associated with durable antibodies.
van der Ploeg K, Kirosingh AS, Mori DAM, Chakraborty S, Hu Z, Sievers BL, Jacobson KB, Bonilla H, Parsonnet J, Andrews JR, Press KD, Ty MC, Ruiz-Betancourt DR, de la Parte L, Tan GS, Blish CA, Takahashi S, Rodriguez-Barraquer I, Greenhouse B, Singh U, Wang TT, Jagannathan P |
Cell reports. Medicine | 2022 |
|
Single-cell profiling of the antigen-specific response to BNT162b2 SARS-CoV-2 RNA vaccine
Kramer KJ, Wilfong EM, Voss K, Barone SM, Shiakolas AR, Raju N, Roe CE, Suryadevara N, Walker LM, Wall SC, Paulo A, Schaefer S, Dahunsi D, Westlake CS, Crowe JE Jr, Carnahan RH, Rathmell JC, Bonami RH, Georgiev IS, Irish JM |
Nature Communications | 2022 |
|
Longitudinal Assessment of SARS-CoV-2-Specific T Cell Cytokine-Producing Responses for 1 Year Reveals Persistence of Multicytokine Proliferative Responses, with Greater Immunity Associated with Disease Severity
Lin J, Law R, Korosec CS, Zhou C, Koh WH, Ghaemi MS, Samaan P, Ooi HK, Matveev V, Yue F, Gingras AC, Estacio A, Buchholz M, Cheatley PL, Mohammadi A, Kaul R, Pavinski K, Mubareka S, McGeer AJ, Leis JA, Heffernan JM, Ostrowski M |
Journal of virology | 2022 |
|
The past, current and future epidemiological dynamic of SARS-CoV-2
Balloux F, Tan C, Swadling L, Richard D, Jenner C, Maini M, van Dorp L |
2022 | |
|
Adaptive Immune Responses and Immunity to SARS-CoV-2
Primorac D, Vrdoljak K, Brlek P, Pavelić E, Molnar V, Matišić V, Erceg Ivkošić I, Parčina M |
Frontiers in immunology | 2022 |
|
Immunological memory to SARS-CoV-2 infection and COVID-19 vaccines.
Sette A, Crotty S |
Immunological Reviews | 2022 |
|
Rituximab‐treated patients with lymphoma develop strong CD8 T‐cell responses following COVID‐19 vaccination
Riise J, Meyer S, Blaas I, Chopra A, Tran TT, Delic\u2010Sarac M, Hestdalen ML, Brodin E, Rustad EH, Dai K, Vaage JT, Nissen\u2010Meyer LS, Sund F, Wader KF, Bjornevik AT, Meyer PA, Nygaard GO, König M, Smeland S, Lund\u2010Johansen F, Olweus J, Kolstad A |
British Journal of Haematology | 2022 |
|
Kinetics of cellular and humoral responses to third BNT162B2 COVID-19 vaccine over six months in heart transplant recipients – implications for the omicron variant
Peled Y, Afek A, Kreiss Y, Rahav G, Nemet I, Kliker L, Indenbaum V, Ram E, Lavee J, Segev A, Matezki S, Sternik L, Raanani E, Lustig Y, Patel JK, Mandelboim M |
The Journal of Heart and Lung Transplantation | 2022 |
|
An Update on Protective Effectiveness of Immune Responses After Recovery From COVID-19
Soleimanian S, Alyasin S, Sepahi N, Ghahramani Z, Kanannejad Z, Yaghobi R, Karimi MH |
Frontiers in immunology | 2022 |
|
Comment on “Multibacillary leprosy unmasked by COVID-19 vaccination”
Hanumanthu V, Narang T, Dogra S |
JAAD Case Reports | 2022 |
|
Humoral Immunogenicity of the mRNA-1273 Vaccine in the Phase 3 Coronavirus Efficacy (COVE) Trial
El Sahly HM, Baden LR, Essink B, Montefiori D, McDermont A, Rupp R, Lewis M, Swaminathan S, Griffin C, Fragoso V, Miller VE, Girard B, Paila YD, Deng W, Tomassini JE, Paris R, Schödel F, Das R, August A, Leav B, Miller JM, Zhou H, Pajon R |
The Journal of Infectious Diseases | 2022 |
|
Antibody and T cell responses to COVID-19 vaccination in patients receiving anticancer therapies
Rouhani SJ, Yu J, Olson D, Zha Y, Pezeshk A, Cabanov A, Pyzer AR, Trujillo J, Derman BA, O'Donnell P, Jakubowiak A, Kindler HL, Bestvina C, Gajewski TF |
Journal for ImmunoTherapy of Cancer | 2022 |
|
Robust SARS-COV-2-specific T-cell immune memory persists long-term in immunocompetent individuals post BNT162b2 double shot
Papadopoulou A, Stavridou F, Giannaki M, Paschoudi K, Chatzopoulou F, Gavriilaki E, Georgolopoulos G, Anagnostopoulos A, Yannaki E |
Heliyon | 2022 |
|
SARS-CoV-2 antibodies and breakthrough infections in the Virus Watch cohort.
Aldridge RW, Yavlinsky A, Nguyen V, Eyre MT, Shrotri M, Navaratnam AMD, Beale S, Braithwaite I, Byrne T, Kovar J, Fragaszy E, Fong WLE, Geismar C, Patel P, Rodger A, Johnson AM, Hayward A |
Nature Communications | 2022 |
|
Heterologous immunity induced by 1st generation COVID-19 vaccines and its role in developing a pan-coronavirus vaccine
Patel RS, Agrawal B |
Frontiers in immunology | 2022 |
|
Heterologous immunization with adenovirus vectored and inactivated vaccines effectively protects against SARS-CoV-2 variants in mice and macaques
He Q, Mao Q, Zhang J, Gao F, Bai Y, Cui B, Liu J, An C, Wang Q, Yan X, Yang J, Song L, Song Z, Liu D, Yuan Y, Sun J, Zhao J, Bian L, Wu X, Huang W, Li C, Wang J, Liang Z, Xu M |
Frontiers in immunology | 2022 |
|
Cell Squeeze: driving more effective CD8 T-cell activation through cytosolic antigen delivery
Park JC, Bernstein H, Loughhead S, Zwirtes R, Jennings J, Nicolini V, Klein C, Deak LC, Umana P, Trumpfheller C, Sharei A |
2022 | |
|
Innate immune responses to three doses of the BNT162b2 mRNA SARS-CoV-2 vaccine
Saresella M, Piancone F, Marventano I, Hernis A, Trabattoni D, Invernizzi M, La Rosa F, Clerici M |
Frontiers in immunology | 2022 |
|
T-Cell Responses Induced by an Intradermal BNT162b2 mRNA Vaccine Booster Following Primary Vaccination with Inactivated SARS-CoV-2 Vaccine.
Sophonmanee R, Ongarj J, Seeyankem B, Seepathomnarong P, Intapiboon P, Surasombatpattana S, Uppanisakorn S, Sangsupawanich P, Chusri S, Pinpathomrat N |
Human vaccines | 2022 |
|
Immunogenicity of COVID‐19 vaccines in chronic liver disease patients and liver transplant recipients: A systematic review and meta‐analysis
Luo D, Chen X, Du J, Mei B, Wang A, Kuang F, Fang C, Gan Y, Peng F, Yang X, Dahmen U, Li B, Song S |
Liver International | 2022 |
|
Naturally occurring spike mutations influence the infectivity and immunogenicity of SARS-CoV-2
Peng Q, Zhou R, Liu N, Wang H, Xu H, Zhao M, Yang D, Au KK, Huang H, Liu L, Chen Z |
Cellular and Molecular Immunology | 2022 |
|
Comparing the B and T cell-mediated immune responses in patients with type 2 diabetes receiving mRNA or inactivated COVID-19 vaccines.
Lee CH, Gray V, Teo JMN, Tam AR, Fong CH, Lui DT, Pang P, Chan KH, Hung IF, Tan KC, Ling GS |
Frontiers in immunology | 2022 |
|
Keeping T Cell Memories in Mind
Mix MR, Harty JT |
Trends in Immunology | 2022 |
|
How Protective are Antibodies to SARS-CoV-2, the Main Weapon of the B-Cell Response?
Pons S, Uhel F, Frapy E, Sérémé Y, Zafrani L, Aschard H, Skurnik D |
Stem Cell Reviews and Reports | 2022 |
|
Early CD4(+) T cell responses induced by the BNT162b2 SARS-CoV-2 mRNA vaccine predict immunological memory.
Bai J, Chiba A, Murayama G, Kuga T, Yahagi Y, Tabe Y, Tamura N, Miyake S |
Scientific Reports | 2022 |
|
Quality of T-Cell Response to SARS-CoV-2 mRNA Vaccine in ART-Treated PLWH
Tortellini E, Zingaropoli MA, Mancarella G, Marocco R, Carraro A, Jamhour M, Barbato C, Guardiani M, Dominelli F, Pasculli P, Napoli A, Gaeta A, Mengoni F, Zuccalà P, Belvisi V, Kertusha B, Parente A, Del Borgo C, Vullo V, Ciardi MR, Mastroianni CM, Lichtner M |
International journal of molecular sciences | 2022 |
|
Humoral and T-cell mediated response after administration of mRNA vaccine BNT162b2 in frail populations
Campagna R, Mazzuti L, Guerrizio G, Nonne C, Migliara G, De Vito C, Mezzaroma I, Chiaretti S, Fimiani C, Pistolesi V, Morabito S, Turriziani O |
2022 | |
|
Immunopeptidome profiling of human coronavirus OC43-infected cells identifies CD4 T cell epitopes specific to seasonal coronaviruses or cross-reactive with SARS-CoV-2
Becerra-Artiles A, Nanaware PP, Muneeruddin K, Weaver GC, Shaffer SA, Calvo-Calle JM, Stern LJ |
2022 | |
|
A systemic review of T-cell epitopes defined from the proteome of SARS-CoV-2
Jin X, Liu X, Shen C |
Virus Research | 2022 |
|
Multipolymer microsphere delivery of SARS-CoV-2 antigens
Shahjin F, Patel M, Machhi J, Cohen JD, Nayan MU, Yeapuri P, Zhang C, Waight E, Hasan M, Abdelmoaty MM, Dash PK, Zhou Y, Andreu I, Gendelman HE, Kevadiya BD |
Acta Biomaterialia | 2022 |
|
Evaluation of Cellular Responses to ChAdOx1-nCoV-19 and BNT162b2 Vaccinations
Lee TH, Nam M, Seo JD, Kim H, Kim HR, Hur M, Yun YM, Moon HW |
Annals of Laboratory Medicine | 2022 |
|
Seasonal respiratory virus circulation was diminished during the COVID‐19 pandemic
Heiskanen A, Galipeau Y, Little J, Mortimer L, Ramotar K, Langlois M, Cooper CL |
Influenza and Other Respiratory Viruses | 2022 |
|
Development of SARS‐CoV‐2 animal vaccines using a stable and efficient NDV expression system
He L, Zhong J, Li G, Lin Z, Zhao P, Yang C, Wang H, Zhang Y, Yang X, Wang Z |
Journal of Medical Virology | 2022 |
|
SARS-CoV-2 immunity and vaccine strategies in people with HIV
Mullender C, da Costa KA, Alrubayyi A, Pett SL, Peppa D |
2022 | |
|
Rapid determination of SARS-CoV-2 Spike T cells in whole blood of vaccinated and naturally infected individuals
Anthony T Tan, Joey M. E. Lim, Nina Le Bert, Kamini Kunasegaran, Adeline Chia, Martin Qui, Nicole Tan, Wan Ni Chia, Ruklanthi de Alwis, Ying Ding, Jean XY Sim, Eng Eong Ooi, Linfa Wang, Mark I-Cheng Chen, Barnaby E Young, Li Yang Hsu, Jenny G Low, David Lye, Antonio Bertoletti |
Journal of Clinical Investigation | 2021 |
|
Humoral and Cellular Immune Responses Against Severe Acute Respiratory Syndrome Coronavirus 2 Variants and Human Coronaviruses After Single BNT162b2 Vaccination
MV Stankov, A Cossmann, A Bonifacius, A Dopfer-Jablonka, GM Ramos, N Gödecke, AZ Scharff, C Happle, AL Boeck, AT Tran, I Pink, MM Hoeper, R Blasczyk, MS Winkler, I Nehlmeier, A Kempf, H Hofmann-Winkler, M Hoffmann, B Eiz-Vesper, S Pöhlmann, GM Behrens |
Clinical Infectious Diseases | 2021 |
|
Human Coronaviruses: Counteracting the Damage by Storm
D Schoeman, BC Fielding |
Viruses | 2021 |
|
The Journal of Clinical Investigation in the time of COVID-19
A Casadevall, S Jackson, GL Semenza, GF Tomaselli, RS Ahima |
Journal of Clinical Investigation | 2021 |
|
SARS-CoV-2-specific T cells in infection and vaccination
A Bertoletti, NL Bert, M Qui, AT Tan |
Cellular and Molecular Immunology | 2021 |
|
Nature of Acquired Immune Responses, Epitope Specificity and Resultant Protection from SARS-CoV-2
RM Gorczynski, RA Lindley, EJ Steele, NC Wickramasinghe |
Journal of Personalized Medicine | 2021 |
|
Assessment of humoral and cellular immunity induced by the BNT162b2 SARS-CoV-2 vaccine in healthcare workers, elderly people, and immunosuppressed patients with autoimmune disease
G Malipiero, A Moratto, M Infantino, P DAgaro, E Piscianz, M Manfredi, V Grossi, E Benvenuti, M Bulgaresi, M Benucci, D Villalta |
Immunologic Research | 2021 |
|
Cross-reactive and mono-reactive SARS-CoV-2 CD4+ T cells in prepandemic and COVID-19 convalescent individuals
A Johansson, U Malhotra, Y Kim, R Gomez, M Krist, A Wald, D Koelle, W Kwok, A Sant |
PLoS pathogens | 2021 |
|
Elucidating T Cell and B Cell Responses to SARS-CoV-2 in Humans: Gaining Insights into Protective Immunity and Immunopathology
A Khanolkar |
Cells | 2021 |
|
The germinal centre B cell response to SARS-CoV-2
BJ Laidlaw, AH Ellebedy |
Nature Reviews Immunology | 2021 |
|
Sind SARS-CoV-2-reaktive T‑Zellen bei Patienten unter Anti-CD20-Therapie mit einer beeinträchtigten humoralen Antwort nachweisbar und potenziell protektiv?
J Braun, T Westhoff, X Baraliakos, N Babel |
Zeitschrift für Rheumatologie | 2021 |
|
Human CD4 + T cells specific for dominant epitopes of SARS‐CoV‐2 Spike and Nucleocapsid proteins with therapeutic potential
J Verhagen, ED Meijden, V Lang, AE Kremer, S Völkl, A Mackensen, M Aigner, AN Kremer |
Clinical & Experimental Immunology | 2021 |
|
Discordant humoral and T cell immune responses to SARS-CoV-2 vaccination in people with multiple sclerosis on anti-CD20 therapy
SP Gadani, M Reyes-Mantilla, L Jank, S Harris, M Douglas, MD Smith, PA Calabresi, EM Mowry, KC Fitzgerald, P Bhargava |
EBioMedicine | 2021 |
|
The BNT162b2 mRNA Vaccine Elicits Robust Humoral and Cellular Immune Responses in People Living With Human Immunodeficiency Virus (HIV)
BA Woldemeskel, AH Karaba, CC Garliss, EJ Beck, KH Wang, O Laeyendecker, AL Cox, JN Blankson |
Clinical Infectious Diseases | 2021 |
|
The Importance of RNA-Based Vaccines in the Fight against COVID-19: An Overview
BA Machado, KV Hodel, LM dos Santos Fonseca, LA Mascarenhas, LP da Silva Andrade, VP Rocha, MB Soares, P Berglund, MS Duthie, SG Reed, R Badaró |
Human vaccines | 2021 |
|
Transient increase in plasma HIV RNA after COVID-19 vaccination with mRNA-1272
G Bozzi, A Lombardi, S Ludovisi, A Muscatello, L Manganaro, D Cattaneo, A Gori, A Bandera |
International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases | 2021 |
|
Heterogeneous Longitudinal Antibody Responses to Covid-19 mRNA Vaccination
SM de la Monte, C Long, N Szczepanski, C Griffin, A Fitzgerald, K Chapin |
2021 | |
|
mRNA vaccine-induced T cells respond identically to SARS-CoV-2 variants of concern but differ in longevity and homing properties depending on prior infection status
J Neidleman, X Luo, M McGregor, G Xie, V Murray, WC Greene, SA Lee, NR Roan |
eLife | 2021 |
|
COVID-19 Vaccination and Glomerulonephritis
N Klomjit, MP Alexander, FC Fervenza, Z Zoghby, A Garg, MC Hogan, SH Nasr, MA Minshar, L Zand |
Kidney International Reports | 2021 |
|
Rapid growth in the COVID-19 era
Y Lee, M Ng, K Daniel, E Wayne |
MRS bulletin / Materials Research Society | 2021 |
|
Anti-COVID-19 Vaccination in Patients with Autoimmune-Autoinflammatory Disorders and Primary/Secondary Immunodeficiencies: The Position of the Task Force on Behalf of the Italian Immunological Societies
R D'Amelio, R Asero, MA Cassatella, B Laganà, C Lunardi, P Migliorini, R Nisini, P Parronchi, I Quinti, V Racanelli, G Senna, A Vacca, E Maggi |
Biomedicines | 2021 |
|
Evaluation of the QuantiFERON SARS-CoV-2 interferon-ɣ release assay in mRNA-1273 vaccinated health care workers
A Krüttgen, H Klingel, G Haase, H Haefner, M Imöhl, M Kleines |
Journal of Virological Methods | 2021 |
|
Rapid induction of antigen-specific CD4+ T cells is associated with coordinated humoral and cellular immunity to SARS-CoV-2 mRNA vaccination
MM Painter, D Mathew, RR Goel, SA Apostolidis, A Pattekar, O Kuthuru, AE Baxter, RS Herati, DA Oldridge, S Gouma, P Hicks, S Dysinger, KA Lundgreen, L Kuri-Cervantes, S Adamski, A Hicks, S Korte, JR Giles, ME Weirick, CM McAllister, J Dougherty, S Long, K DAndrea, JT Hamilton, MR Betts, P Bates, SE Hensley, A Grifoni, D Weiskopf, A Sette, AR Greenplate, EJ Wherry |
Immunity | 2021 |
|
Long-Lasting Immunity Against SARS-CoV-2: Dream or Reality?
D Gussarow, A Bonifacius, A Cossmann, MV Stankov, P Mausberg, S Tischer-Zimmermann, N Gödecke, U Kalinke, GM Behrens, R Blasczyk, B Eiz-Vesper |
Frontiers in Medicine | 2021 |
|
Potency of BNT162b2 and mRNA‐1273 vaccine‐induced neutralizing antibodies against severe acute respiratory syndrome‐CoV‐2 variants of concern: A systematic review of in vitro studies
M Noori, SA Nejadghaderi, S Arshi, K CarsonChahhoud, K Ansarin, AA Kolahi, S Safiri |
Reviews in Medical Virology | 2021 |
|
Vaccination against SARS-CoV-2 should be included in childhood vaccination programs
E Petersen, P Buchy |
International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases | 2021 |
|
Minimal cross-over between mutations associated with Omicron variant of SARS-CoV-2 and CD8+ T cell epitopes identified in COVID-19 convalescent individuals
Redd AD, Nardin A, Kared H, Bloch EM, Abel B, Pekosz A, Laeyendecker O, Fehlings M, Quinn TC, Tobian AA |
2021 | |
|
mRNA vaccine-induced T cells respond identically to SARS-CoV-2 variants of concern but differ in longevity and homing properties depending on prior infection status
Neidleman J, Luo X, McGregor M, Xie G, Murray V, Greene WC, Lee SA, Roan NR |
2021 | |
|
SARS-CoV-2 Infections in mRNA Vaccinated Individuals are Biased for Viruses Encoding Spike E484K and Associated with Reduced Infectious Virus Loads that Correlate with Respiratory Antiviral IgG levels.
Mostafa HH, Luo CH, Morris CP, Li M, Swanson NJ, Amadi A, Gallagher N, Pekosz A |
2021 | |
|
SARS -CoV-2 T-cell immunity to variants of concern following vaccination.
Gallagher KME, Leick MB, Larson RC, Berger TR, Katsis K, Yam JY, Brini G, Grauwet K, Maus MV |
bioRxiv : the preprint server for biology | 2021 |
|
Discordant humoral and T cell immune responses to SARS-CoV-2 vaccination in people with multiple sclerosis on anti-CD20 therapy.
Gadani SP, Reyes-Mantilla M, Jank L, Harris S, Douglas M, Smith MD, Calabresi PA, Mowry EM, Fitzgerald KC, Bhargava P |
medRxiv : the preprint server for health sciences | 2021 |
Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)